Daewon Pharmaceutical announced that a delegation from the Vietnamese government and pharmaceutical industry visited its Jincheon plant in North Chungcheong Province on September 11 to tour its advanced pharmaceutical production facilities and quality control systems.
The delegation included officials from the Vietnam Ministry of Health's Drug Administration (DAV) and representatives from pharmaceutical and bio companies such as Newteco and Phitopharma. They visited the Jincheon plant to benchmark Korea's advanced pharmaceutical production facilities and operational systems in connection with Vietnam's ongoing pharmaceutical and bio industrial park development project, and to explore potential collaboration with domestic pharmaceutical companies.
Daewon Pharmaceutical showcased its smart factory initiatives, focusing on the plant's automated production equipment and IT-based quality control systems. Opened in 2019, the Jincheon plant is the largest production base for liquid medications in Korea, producing Daewon's flagship products, including the oral medication Cold Daewon. It features state-of-the-art facilities and production systems that meet cGMP standards.
cGMP refers to the manufacturing and quality control standards required by the U.S. Food and Drug Administration (FDA) to ensure the safety and quality of pharmaceuticals, encompassing management standards for the entire production process from raw material receipt to manufacturing, packaging, testing, and storage.
The Jincheon plant has implemented a range of automation technologies, including a raw material transfer system (TDS), conveyor systems, packaging automation robots, and a warehouse management system (WMS), enhancing efficiency across the entire production process from preparation to packaging and logistics. Additionally, it employs IT-based systems such as quality management systems (QMS), laboratory information management systems (LIMS), and environmental management systems (BMS) to systematically manage quality, testing, and manufacturing environments.
Baek In-hwan, president of Daewon Pharmaceutical, stated, "This was an opportunity to directly introduce the advanced production facilities and operational capabilities of the Jincheon plant to the Vietnamese government and industry officials promoting the establishment of a pharmaceutical and bio industrial park. We aim to expand our collaboration with overseas partners based on our smart factory competitiveness and to raise awareness of the excellence of products produced at the Jincheon plant."
Meanwhile, Daewon Pharmaceutical is noteworthy for expanding its prescription drug portfolio, which has traditionally focused on respiratory and antipyretic analgesics, to include chronic diseases. In the second quarter of this year, the endocrine and circulatory system accounted for 25.1% of the company's sales by disease category, surpassing the respiratory system's 24.4%. In the previous quarter, the respiratory system accounted for 26.6%, while metabolic diseases represented 22.9%. The company plans to establish new growth avenues by developing new drugs for gastroesophageal reflux disease and obesity-related metabolic disorders.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.